PATENT CLAIM ANALYSIS

Application Number: 16013165
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-10
Patent Classification: ["424", "489000"]

Abstract:
Methods of treating atrial arrhythmia include administering an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof, such that the at least one antiarrhythmic pharmaceutical agent first enters the heart through the pulmonary vein to the left atrium. Other methods of treating atrial arrhythmia include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. An amount of the at least one antiarrhythmic pharmaceutical agent may peak in the coronary sinus of the heart at a time ranging from 10 seconds to 30 minutes from initiation of the administering. Unit doses, aerosols, and kits are also contemplated.

Claim (Index 8):
The pharmaceutical composition of  claim 1 , wherein a concentration of flecainide is higher than a second concentration of flecainide that is effective when administered intravenously for cardioversion of the atrial arrhythmia in the subject.

Metadata:
- Claim Count in Document: 3.0
- Percentile: 94.0
- Lexical Diversity: 1.98333
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13257249', '14632252', '15976516', '15928851', '15422053']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8094019625977009
- 35 USC 102 Novelty (BERT): 0.5833786992598993
- Combined Prediction Score: 0.7867996362639207
- Mean Citation Score: 430.420086
- Max Citation Score: 561.1576
- Similarity Product: 389.4785979331493

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test